STOCK TITAN

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that President & CEO John Tucker will present at the H.C.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that President & CEO John Tucker will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting at 7am EDT on September 13. scPharmaceuticals focuses on developing products aimed at optimizing infused therapies, advancing patient care, and reducing healthcare costs, particularly in heart failure and infectious disease treatments.

Loading...
Loading translation...
Argus Session date unavailable
+1.75% session move Open Argus
Details

News Market Reaction – SCPH

The recorded move for SCPH in the trading session of this news was +1.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Event:

H.C. Wainwright 23rd Annual Global Investment Conference
Monday, September 13 – Wednesday, September 15
A webcast of Mr. Tucker’s presentation will be available on-demand as of 7am EDT, Monday, September 13. It can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the H.C. Wainwright 23rd Annual Global Investment Conference?

The conference will be held virtually from September 13-15, 2021.

Who will represent scPharmaceuticals at the conference?

John Tucker, the President & CEO of scPharmaceuticals, will present at the conference.

How can I access John Tucker's presentation?

The presentation will be available on-demand starting at 7am EDT on September 13, accessible on scPharmaceuticals' Investor Relations website.

What is the focus of scPharmaceuticals' products?

scPharmaceuticals focuses on developing products that optimize infused therapies and improve health outcomes, particularly for heart failure and infectious diseases.

What does scPharmaceuticals aim to achieve?

The company aims to advance patient care and reduce healthcare costs through innovative self-administration of IV-strength treatments.

Keep reading